Autor: "Ng TI" - OpacWWW - Prolib Integro

Skocz do pozycji: 1.

Tytuł:: A prospective multicentre study testing the diagnostic accuracy of an automated cough sound centred analytic system for the identification of common respiratory disorders in children
Autorzy:: Porter, PaulAff1, Aff2, Aff3
Abeyratne, Udantha
Swarnkar, Vinayak
Tan, Jamie
Ng, Ti-wan
Brisbane, Joanna M.
Speldewinde, Deirdre
Choveaux, Jennifer
Sharan, Roneel
Kosasih, Keegan
Della, Phillip; Pokaż więcej
Źródło:: Respiratory Research. 20(1)

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 2.

Tytuł:: Demonstration of a low-complexity memory-polynomial-aided neural network equalizer for CAP visible-light communication with superluminescent diode
Autorzy:: Hu Fangchen
Holguin-Lerma Jorge A.
Mao Yuan
Zou Peng
Shen Chao
Ng Tien Khee
Ooi Boon S.
Chi Nan; Pokaż więcej
Temat:: superluminescent diode
visible-light communication
neural network
Optics. Light
QC350-467
Źródło:: Opto-Electronic Advances, Vol 3, Iss 8, Pp 200009-1-200009-11 (2020)
Opis pliku:: electronic resource
Relacje:: https://doaj.org/toc/2096-4579
Dostęp URL:: https://doaj.org/article/aa8c947510b24f89bcc10ccf32d0f38d Link otwiera się w nowym oknie

Czasopismo naukowe

na półce

Szczegóły

Skocz do pozycji: 3.

Informacja:: Dostęp do tej pozycji wymaga zalogowania się.

Czasopismo naukowe

na półce

Szczegóły

Skocz do pozycji: 4.

Informacja:: Dostęp do tej pozycji wymaga zalogowania się.

Czasopismo naukowe

na półce

Szczegóły

Skocz do pozycji: 5.

Informacja:: Dostęp do tej pozycji wymaga zalogowania się.

Czasopismo naukowe

na półce

Szczegóły

Skocz do pozycji: 6.

Informacja:: Dostęp do tej pozycji wymaga zalogowania się.

Czasopismo naukowe

na półce

Szczegóły

Skocz do pozycji: 7.

Informacja:: Dostęp do tej pozycji wymaga zalogowania się.

Czasopismo naukowe

na półce

Szczegóły

Skocz do pozycji: 8.

Tytuł:: Survey of childhood empyema in Asia: Implications for detecting the unmeasured burden of culture-negative bacterial disease
Autorzy:: Shen Xuzhuang
Chiu Chen-Hsun
Anh Dang
Yong Dong
Kilgore Paul E
Nyambat Batmunkh
Jodar Luis
Ng Timothy L
Bock Hans L
Hausdorff William P; Pokaż więcej
Temat:: Infectious and parasitic diseases
RC109-216
Źródło:: BMC Infectious Diseases, Vol 8, Iss 1, p 90 (2008)
Opis pliku:: electronic resource
Relacje:: http://www.biomedcentral.com/1471-2334/8/90; https://doaj.org/toc/1471-2334
Dostęp URL:: https://doaj.org/article/4d6bad22809449cba8d7dad07a052d77 Link otwiera się w nowym oknie

Czasopismo naukowe

na półce

Szczegóły

Skocz do pozycji: 9.

Tytuł:: Antiviral Drug Discovery for the Treatment of COVID-19 Infections.
Autorzy:: Ng TI; Virology Drug Discovery, AbbVie Inc., North Chicago, IL 60064, USA.
Correia I; Department of Cell and Protein Sciences, Drug Discovery Science and Technology, AbbVie Inc., Worcester, MA 01605, USA.
Seagal J; Department of Biologics Discovery, Drug Discovery Science and Technology, AbbVie Inc., Worcester, MA 01605, USA.
DeGoey DA; Department of Centralized Medicinal Chemistry, Drug Discovery Science and Technology, AbbVie Inc., North Chicago, IL 60064, USA.
Schrimpf MR; Department of Centralized Medicinal Chemistry, Drug Discovery Science and Technology, AbbVie Inc., North Chicago, IL 60064, USA.
Hardee DJ; Department of Centralized Medicinal Chemistry, Drug Discovery Science and Technology, AbbVie Inc., North Chicago, IL 60064, USA.
Noey EL; Department of Structural Biology, Drug Discovery Science and Technology, AbbVie Inc., North Chicago, IL 60064, USA.
Kati WM; Virology Drug Discovery, AbbVie Inc., North Chicago, IL 60064, USA.; Pokaż więcej
Źródło:: Viruses [Viruses] 2022 May 04; Vol. 14 (5). Date of Electronic Publication: 2022 May 04.
Typ publikacji:: Journal Article; Review; Research Support, Non-U.S. Gov't
MeSH Terms:: Antiviral Agents*/pharmacology
Drug Discovery*
COVID-19 Drug Treatment*
COVID-19 Vaccines ; Coronavirus 3C Proteases/antagonists & inhibitors ; Humans ; RNA-Dependent RNA Polymerase/antagonists & inhibitors ; SARS-CoV-2 ; Spike Glycoprotein, Coronavirus/antagonists & inhibitors ; Viral Proteins/metabolism
SCR Organism:: SARS-CoV-2 variants

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 10.

Tytuł:: Sequence Analysis of the Fusion Protein Gene of Human Respiratory Syncytial Virus Circulating in China from 2003 to 2014.
Autorzy:: Song J; WHO WPRO Regional Reference Measles/Rubella Laboratory and Key Laboratory of Medical Virology, National Health Commission of the People's Republic of China, National Institute for Viral Disease Control and Prevention, China Center for Disease Control and Prevention, Beijing, People's Republic of China.
Wang H; WHO WPRO Regional Reference Measles/Rubella Laboratory and Key Laboratory of Medical Virology, National Health Commission of the People's Republic of China, National Institute for Viral Disease Control and Prevention, China Center for Disease Control and Prevention, Beijing, People's Republic of China.
Ng TI; AbbVie, Inc, North Chicago, IL, USA.
Cui A; WHO WPRO Regional Reference Measles/Rubella Laboratory and Key Laboratory of Medical Virology, National Health Commission of the People's Republic of China, National Institute for Viral Disease Control and Prevention, China Center for Disease Control and Prevention, Beijing, People's Republic of China.
Zhu S; WHO WPRO Regional Reference Measles/Rubella Laboratory and Key Laboratory of Medical Virology, National Health Commission of the People's Republic of China, National Institute for Viral Disease Control and Prevention, China Center for Disease Control and Prevention, Beijing, People's Republic of China.
Huang Y; Jilin Children's Medical Center, Children's Hospital of Changchun, Changchun, People's Republic of China.
Sun L; Jilin Children's Medical Center, Children's Hospital of Changchun, Changchun, People's Republic of China.
Yang Z; State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, People's Republic of China.
Yu D; Gansu Provincial Centers for Disease Control and Prevention, Lanzhou, People's Republic of China.
Yu P; Shaanxi Provincial Centers for Disease Control and Prevention, Xian, People's Republic of China.
Zhang H; Hunan Provincial Centers for Disease Control and Prevention, Changsha, People's Republic of China.
Zhang Y; WHO WPRO Regional Reference Measles/Rubella Laboratory and Key Laboratory of Medical Virology, National Health Commission of the People's Republic of China, National Institute for Viral Disease Control and Prevention, China Center for Disease Control and Prevention, Beijing, People's Republic of China. .
Xu W; WHO WPRO Regional Reference Measles/Rubella Laboratory and Key Laboratory of Medical Virology, National Health Commission of the People's Republic of China, National Institute for Viral Disease Control and Prevention, China Center for Disease Control and Prevention, Beijing, People's Republic of China. wenbo_.; Pokaż więcej
Źródło:: Scientific reports [Sci Rep] 2018 Dec 04; Vol. 8 (1), pp. 17618. Date of Electronic Publication: 2018 Dec 04.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Genetic Variation*
Sequence Analysis*
Respiratory Syncytial Virus Infections/*virology
Respiratory Syncytial Virus, Human/*genetics
Viral Fusion Proteins/*genetics
China ; Cluster Analysis ; Genotype ; Humans ; Phylogeny ; Respiratory Syncytial Virus, Human/isolation & purification

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 11.

Tytuł:: Hepatitis C virus genetic diversity by geographic region within genotype 1-6 subtypes among patients treated with glecaprevir and pibrentasvir.
Autorzy:: Schnell G; Research & Development, AbbVie Inc., North Chicago, Illinois, United States of America.
Krishnan P; Research & Development, AbbVie Inc., North Chicago, Illinois, United States of America.
Tripathi R; Research & Development, AbbVie Inc., North Chicago, Illinois, United States of America.
Beyer J; Research & Development, AbbVie Inc., North Chicago, Illinois, United States of America.
Reisch T; Research & Development, AbbVie Inc., North Chicago, Illinois, United States of America.
Irvin M; Research & Development, AbbVie Inc., North Chicago, Illinois, United States of America.
Dekhtyar T; Research & Development, AbbVie Inc., North Chicago, Illinois, United States of America.
Lu L; Research & Development, AbbVie Inc., North Chicago, Illinois, United States of America.
Ng TI; Research & Development, AbbVie Inc., North Chicago, Illinois, United States of America.
Xie W; Research & Development, AbbVie Inc., North Chicago, Illinois, United States of America.
Pilot-Matias T; Research & Development, AbbVie Inc., North Chicago, Illinois, United States of America.
Collins C; Research & Development, AbbVie Inc., North Chicago, Illinois, United States of America.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2018 Oct 04; Vol. 13 (10), pp. e0205186. Date of Electronic Publication: 2018 Oct 04 (Print Publication: 2018).
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Genetic Variation*
Hepacivirus/*drug effects
Hepatitis C, Chronic/*drug therapy
Viral Nonstructural Proteins/*genetics
Amino Acid Substitution/genetics ; Aminoisobutyric Acids ; Benzimidazoles/administration & dosage ; Cyclopropanes ; Drug Resistance, Viral/genetics ; Genotype ; Hepacivirus/genetics ; Hepacivirus/pathogenicity ; Hepatitis C, Chronic/epidemiology ; Hepatitis C, Chronic/genetics ; Hepatitis C, Chronic/virology ; Humans ; Lactams, Macrocyclic ; Leucine/analogs & derivatives ; Phylogeny ; Proline/analogs & derivatives ; Pyrrolidines ; Quinoxalines/administration & dosage ; Sulfonamides/administration & dosage ; Viral Nonstructural Proteins/chemistry

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 12.

Tytuł:: Resistance Analysis of a 3-Day Monotherapy Study with Glecaprevir or Pibrentasvir in Patients with Chronic Hepatitis C Virus Genotype 1 Infection.
Autorzy:: Ng TI; AbbVie, Inc., North Chicago, IL 60064, USA. teresa.ng@abbvie.com.
Pilot-Matias T; AbbVie, Inc., North Chicago, IL 60064, USA. .
Tripathi R; AbbVie, Inc., North Chicago, IL 60064, USA. .
Schnell G; AbbVie, Inc., North Chicago, IL 60064, USA. .
Krishnan P; AbbVie, Inc., North Chicago, IL 60064, USA. .
Reisch T; AbbVie, Inc., North Chicago, IL 60064, USA. .
Beyer J; AbbVie, Inc., North Chicago, IL 60064, USA. .
Dekhtyar T; AbbVie, Inc., North Chicago, IL 60064, USA. .
Irvin M; AbbVie, Inc., North Chicago, IL 60064, USA. .
Lu L; AbbVie, Inc., North Chicago, IL 60064, USA. .
Asatryan A; AbbVie, Inc., North Chicago, IL 60064, USA. .
Campbell A; AbbVie, Inc., North Chicago, IL 60064, USA. .
Yao B; AbbVie, Inc., North Chicago, IL 60064, USA. .
Lovell S; AbbVie, Inc., North Chicago, IL 60064, USA. .
Mensa F; AbbVie, Inc., North Chicago, IL 60064, USA. .
Lawitz EJ; Texas Liver Institute, University of Texas Health San Antonio, San Antonio, TX 78215, USA. .
Kort J; AbbVie, Inc., North Chicago, IL 60064, USA. .
Collins C; AbbVie, Inc., North Chicago, IL 60064, USA. .; Pokaż więcej
Źródło:: Viruses [Viruses] 2018 Aug 28; Vol. 10 (9). Date of Electronic Publication: 2018 Aug 28.
Typ publikacji:: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Benzimidazoles/*pharmacokinetics
Drug Resistance, Multiple, Viral/*genetics
Hepacivirus/*drug effects
Hepatitis C, Chronic/*drug therapy
Quinoxalines/*pharmacokinetics
Sulfonamides/*pharmacokinetics
Amino Acid Substitution/drug effects ; Aminoisobutyric Acids ; Antiviral Agents/administration & dosage ; Antiviral Agents/pharmacokinetics ; Antiviral Agents/therapeutic use ; Benzimidazoles/administration & dosage ; Benzimidazoles/therapeutic use ; Cyclopropanes ; Drug Therapy, Combination ; Fibrosis ; Genotype ; Hepacivirus/genetics ; Hepatitis C, Chronic/blood ; Hepatitis C, Chronic/pathology ; Humans ; Lactams, Macrocyclic ; Leucine/analogs & derivatives ; Liver/pathology ; Proline/analogs & derivatives ; Pyrrolidines ; Quinoxalines/administration & dosage ; Quinoxalines/therapeutic use ; RNA, Viral/genetics ; Sulfonamides/administration & dosage ; Sulfonamides/therapeutic use ; Viral Load/drug effects

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 13.

Tytuł:: High antiviral activity of NS5A inhibitor ABT-530 with paritaprevir/ritonavir and ribavirin against hepatitis C virus genotype 3 infection.
Autorzy:: Poordad F; Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX, USA.
Landis CS; Division of Gastroenterology, University of Washington, Seattle, WA, USA.
Asatryan A; AbbVie Inc., North Chicago, IL, USA.
Jackson DF 3rd; Digestive Health Specialists of the Southeast, Dothan, AL, USA.
Ng TI; AbbVie Inc., North Chicago, IL, USA.
Fu B; AbbVie Inc., North Chicago, IL, USA.
Lin CW; AbbVie Inc., North Chicago, IL, USA.
Yao B; AbbVie Inc., North Chicago, IL, USA.
Kort J; AbbVie Inc., North Chicago, IL, USA.; Pokaż więcej
Źródło:: Liver international : official journal of the International Association for the Study of the Liver [Liver Int] 2016 Aug; Vol. 36 (8), pp. 1125-32. Date of Electronic Publication: 2016 Feb 03.
Typ publikacji:: Clinical Trial, Phase II; Journal Article; Multicenter Study
MeSH Terms:: Antiviral Agents/*pharmacology
Benzimidazoles/*pharmacology
Hepatitis C, Chronic/*drug therapy
Protease Inhibitors/*pharmacology
Pyrrolidines/*pharmacology
Adult ; Aged ; Cyclopropanes ; Drug Therapy, Combination ; Female ; Genotype ; Hepacivirus/genetics ; Humans ; Lactams, Macrocyclic ; Macrocyclic Compounds/pharmacology ; Male ; Middle Aged ; Proline/analogs & derivatives ; Ribavirin/pharmacology ; Ritonavir/pharmacology ; Sulfonamides ; Sustained Virologic Response ; United States

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Informacja

Wyszukujesz frazę ""Ng TI"" wg kryterium: Autor

Źródło danych

Ogranicz do:

Ogranicz do bazy

Typ dokumentu

Temat

Wydawca

Publikacja

Język